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The ACIN1 Gene is Hypermethylated in Early Stage Lung
Adenocarcinoma
Yujian Shu, MD,* Tatsuo Iijima, MD,* Weihong Sun, MD,* Junko Kano, MD,*
Tadashi Ishiyama, MS,* Chigusa Okubo, MS,* Yoichi Anami, MD,* Ryota Tanaka, MD,†
Shimao Fukai, MD,‡ and Masayuki Noguchi, MD*
Introduction and Hypothesis: In recent years, many studies have
performed genome-wide searching for differentially methylated
genes in cancer. We hypothesized that characteristic aberrant hyper-
methylation of CpG islands of certain genes may exist in the early
stages of lung adenocarcinoma and that such alterations may be
useful in the detection and treatment of early lung adenocarcinoma.
Methods: A pair of immortalized cell lines originating from atypical
adenomatous hyperplasia (PL16T) and from the resected end of the
bronchus of the same patient (PL16B) was searched for aberrantly
and differentially hypermethylated DNA fragments by a combina-
tion of the methylated CpG island amplification and suppression
subtractive hybridization methods.
Results: From 229 clones, we selected 15 fragments that had a
genomic region meeting the criteria for a CpG island. We identified
a gene, apoptotic chromatin condensation inducer 1 (ACIN1), that
was hypermethylated in PL16T. A higher frequency of hypermeth-
ylation at a locus at the 5= end of the DNA fragment isolated from
the ACIN1 gene was found in small-sized adenocarcinoma (2 cm or
less) (30/37, 81%) compared with normal lung tissue (9/37, 24%,
p  0.05). Interestingly, hypermethylation of ACIN1 was detected
relatively frequently in the normal counterpart of adenocarcinoma
without bronchioloalveolar carcinoma (BAC) component (7/16,
44%), but was rare in the normal counterpart of adenocarcinoma
with BAC component (2/21, 10%, P  0.05).
Conclusions: We found hypermethylation of the ACIN1 gene in
early stage lung adenocarcinoma. The role of methylation status in
the development and malignant transformation of lung adenocarci-
noma requires clarification.
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Lung cancer is one of the major causes of death in manycountries. The total number of cancer deaths in Japan
exceeds 300,000 per year, and mortality from lung cancer
accounts for 20% of this total and is predicted to increase in
the future. At the same time, 5-year survival rates of more
than 80% are seen in patients with stage I lung cancer, and
advances in early diagnosis and treatment are expected to
improve these rates. Detection of cancer at earlier stages
could potentially increase survival rates. Conventional meth-
ods of screening for lung cancer by chest X-ray and sputum
cytology have proven ineffective in increasing survival
rates,1,2 so it is important to find more sensitive and specific
diagnostic methods that can be used to detect the earliest
stages of the disease.
One DNA-based alteration that commonly occurs in
cancer is DNA methylation, an epigenetic modification of
DNA. DNA methylation is a covalent chemical modification,
resulting in a methyl (CH3) group at the carbon-5 position of
cytosine. CpG islands are CpG-rich areas of 0.5 to 5 kb in
length that occur on average every 100 kb.3,4 CpG islands are
usually unmethylated. Approximately half of all human genes
have CpG islands,5 which are usually present in both house-
keeping genes and tissue-specific genes.6 Most studies per-
formed in this area have examined individual aberrant meth-
ylated genes associated with cancer. Increased methylation in
the promoter region of a gene leads to reduced expression,
whereas methylation in the transcribed region has a variable
effect on gene expression.7,8,9 DNA methylation in lung
cancer has been widely studied. To date, more than 30 genes
have been found to have hypermethylation in their promoter
region in lung cancer.9,10 Hypermethylation of the APC,
CDKN2A, CHD13, RARB, and RASSF1A genes is found in
over 30% of patients with lung cancer, as established by at
least two independent studies.10 However, methylation does
not guarantee gene silencing.11 One reason for the great
interest in DNA hypermethylation of CpG islands is its
potential applicability as an epigenetic marker of cancer, and
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it has been suggested that the analysis of DNA methylation
patterns could become a powerful tool for accurate diagnosis
of early lung cancer.10
In recent years, many studies have involved genome-
wide searching for differentially methylated genes in cancer.
Toyota and colleagues applied methylated CpG island ampli-
fication (MCA) coupled with representational difference
analysis (RDA) to identify novel CpG islands differentially
methylated in tumors.12–15 Ushijima and colleagues identified
hypo- or hyper-methylated genomic fragments in tumors by a
methylation-sensitive representational difference analysis
(MS-RDA) method using the methylation-sensitive restric-
tion enzyme Hpa II.16–18
We hypothesized that characteristic aberrant hyper-
methylation of CpG islands of genes may occur in the early
stages of lung adenocarcinoma and that such alterations may
be useful in the detection and treatment of early adenocarci-
noma. The aim of this study was to isolate aberrantly meth-
ylated CpG islands in lung adenocarcinoma by genome-wide
analysis and to identify the characteristics of lung cancer that
are associated with methylation status. The initial search for
aberrant methylation was performed with a pair of cell lines,
PL16T, which was derived from atypical adenomatous hy-
perplasia (AAH), and PL16B, which was derived from the
resected end of the normal bronchus in the same patient.19
MATERIALS AND METHODS
Tissue Samples, Cell Line And Histological
Classification
A pair of cell lines, PL16T derived from AAH and
PL16B derived from the resected end of the bronchus of the
same patient who was 56-years old female and never smoker
were used for the subtractive analysis for hypermethylated
CpG islands.19 Thirty-seven pairs of small-sized lung adeno-
carcinoma, less than 2 cm in diameter, and the adjacent
noncancerous tissue were obtained from a bank of surgically
resected material at the University Hospital of Tsukuba
(Ibaraki, Japan) and Ibarakihigashi National Hospital
(Ibaraki, Japan). All patients gave informed consent for
specimen collection. The samples were from 22 male and 15
female patients (average age, 63.3 years; females, 62.6 years;
males, 63.8 years). They underwent surgery during the period
from April 1996 to October 2003. All tumor specimens were
classified histologically according to the WHO histological
classification and the histological criteria for small-sized lung
adenocarcinoma proposed by Noguchi et al.20 Noguchi et al.
divided small adenocarcinomas into two groups. One is
adenocarcinoma with replacement growth and the other is
adenocarcinoma without replacement growth, which shows
destructive growth at the margin of the tumor. As replace-
ment growth indicates bronchiolo-alveolar spreading and/or
lepidic growth, we divided the tumors examined in this study
into adenocarcinoma with bronchioloalveolar carcinoma
(BAC) component and adenocarcinoma without BAC com-
ponent. All of the surgically resected specimens were fixed
with formalin and embedded in paraffin. Additional metha-
nol-fixed specimens and fresh frozen materials were prepared
for the DNA and RNA analyses. Genomic DNA was ex-
tracted by standard phenol/chloroform procedures from the
PL16T and PL16B cell lines and the tissue specimens. Total
RNA was extracted from each frozen tissue or cell line with
Trizol (Invitrogen Corp., Carlsbad, CA).
Methylated Cpg Island Amplification (MCA) Of
The Pl16t And Pl16b Cell Lines
MCA was performed as described by Toyota et al.13
Briefly, 5 g of DNA extracted from the PL16T or PL16B
cell lines was first digested with Sma I, which is a methyla-
tion-sensitive restriction enzyme, then digested again with the
methylation-insensitive Sma I isoschizomer Xma I (New
England Biolabs, Inc., Beverly, MA). The restriction frag-
ments (0.5 g) were ligated to RXMA12/24 (RXMA24:
5=-AGCACTCTCCAGCCTCTCACCGAC-3=; RXMA12:
5=-CCGGGTCGGTGA-3=) or RMCA 12/24 (RMCA24: 5=-
CCACCGCCATCCGAGCCTTTCTGC-3=; RMCA12: 5=-
CCGGGCAGAAAG-3=) adaptors with T4 ligase (New En-
gland Biolabs, Inc.) and amplified by PCR.
Modified Suppression Subtractive
Hybridization (SSH) Between Pl16t And Pl16b
Mca Amplicons
SSH was originally developed as a PCR-based method
for cDNA subtraction analysis.21,22 In this study, we com-
pared two populations of DNA by this system (CLONTECH
PCR-SelectTM cDNA Subtraction Kit; BD Bioscience Clon-
tech, Palo Alto, CA, USA) with some modifications. In brief,
MCA amplicons were digested with the restriction endonu-
clease Sma I to remove the RMCA 24mer adaptor or the
RXMA 24mer adaptor and purified by Microcon YM-100
filtration (Millipore, Billerica, MA). Two-directional (for-
ward and reverse) subtractive hybridization and unsubtractive
hybridization were performed between PL16T and PL16B
according to the manufacturer’s instructions, and the subtrac-
tive hybridization products were amplified by PCR. First,
diluted tester DNA (MCA amplicon of PL16T) was ligated to
adaptor with T4 DNA ligase (both from the CLONTECH
PCR-SelectTM cDNA Subtraction Kit). The subtraction con-
sists of three steps. 1) First hybridization: an excess of driver
DNA (MCA amplicon of PL16B) is hybridized with adaptor-
ligated tester. 2) Second hybridization: an excess of fresh
denatured driver DNA is mixed with adaptor-ligated tester
DNA and hybridized. 3) PCR amplification: the first and
second PCR amplifications are used to amplify exponentially
molecules with different adaptor sequences, further reducing
the background and enriching for differentially methylated
sequences. Forward- and reverse-subtracted DNA and for-
ward- and reverse-unsubtracted DNA were used as templates.
The primer sequences used in the first PCR amplification
were as follows: PCR primer 1, 5=-CTAATACGACTCAC-
TATAGGG-3=. The primer 1 sequence was used as both
forward and reverse primers. The first PCR products were
diluted and subjected to a second PCR amplification. Primer
sequences were as follows: nested PCR primer 1, 5=-TC-
GAGCGGCCGCCCGGGCAGGT-3=; nested PCR primer
2R, 5=-AGCGTGGTGCGGCCGAGGT-3=.
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Cloning And Differential Screening For Ssh
Products
The secondary PCR products (forward subtracted MCA
amplicon of PL16T) were inserted into the pCR2.1 vector by
use of a T/A cloning kit (Invitrogen Corp., Carlsbad, CA) and
the plasmids were transformed into One Shot® DH5-T1R E.
coli (Invitrogen Corp., Carlsbad, CA). The 2134 bacterial
colonies were picked up and their insert DNA was amplified
by PCR and blotted onto nylon membranes (Osmonics, Inc.,
Tokyo, Japan) and hybridized with forward- and reverse-
subtracted and both unsubtracted probes. Then, a PCR-Se-
lectTM Differential Screening Kit (BD Bioscience Clontech)
was used to screen clones with different DNA fragments
inserted, according to the manufacturer’s instructions.
Sequencing And Analysis
Two hundred and twenty nine clones were selected for
sequence analysis. These insert fragments were sequenced
with a BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and an ABI PRISM
310 Genetic Analyzer (Applied Biosystems Japan Ltd., To-
kyo, Japan). Sequence homologies were identified with the
BLAST program of the National Center for Biotechnology
Information, available at http://www.ncbi.nlm.nih.gov/
BLAST/.
Bisulfite Sequencing Of Acin1 Gene Clones
DNA was isolated by standard phenol-chloroform ex-
traction and ethanol precipitation from surgically resected
specimens of peripheral-type lung adenocarcinoma tissue and
adjacent normal tissue from 37 patients. Genomic DNA was
modified by treatment with sodium bisulfite.23 We sequenced
3 to 5 clones from each of the specimens. The insert DNA
fragments were amplified by PCR with Takara Ex TaqTM Hot
Start polymerase (Takara Bio Inc., Tokyo, Japan). The primer
sequence used in amplification of the ACIN1 gene was as
follows: forward, 5=-ATTAAGATAGAGGAGTAGGGA-
ATATT-3=; reverse, 5=-CCTACCTTTCTTCTCACTCT-
TCTTT-3=. Then, the PCR products were ligated into the
pCR2.1 vector (Invitrogen Corp., Carlsbad, CA) and the
plasmid was transformed into One Shot® INVF’ E. coli
(Invitrogen Corp.). Five clones for each sample were se-
quenced with a BigDye® Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems) and an ABI PRISM 310 Genetic
Analyzer (Applied Biosystems Japan, Ltd.).
Quantitative Real-time Rt-PCR Analysis
Total RNA was prepared with Trizol (Invitrogen Corp.)
and 1g samples were used for cDNA synthesis with random
hexamers primer (TaqMan Reverse Transcription Reagents
Kit; Applied Biosystems Japan, Ltd.). The primer sequences
used were as follows: ACIN1-F, 5=-GGATCGGGACAAA-
GTTCGAGA-3=; ACIN1-R, 5=-CAGTGGGAGCCAATA-
GATGCAG-3=. Quantitative real-time RT-PCR was per-
formed with SYBR Premix Ex TaqTM kit (Perfect Real Time;
Takara Bio Inc.) and a Gene Amp 5700 sequence detection
system (Applied Biosystems Japan, Ltd.). Numbers of target
cDNA molecules were normalized to numbers of GAPDH
cDNA molecules as a control.
Statistical Analysis
Associations of categoric variables were evaluated with
Fisher’s exact probability test. A P-value of 0.05 was taken
to signify statistical significance.
FIGURE 1. a: Phase-contrast mi-
crophotograph of PL16T which is a
immortalized cell line derived from
atypical adenomatous hyperplasia.
(original magnification x100) b:
Phase-contrast microphotograph
of PL16B which is a immortalized
cell line derived from the resected
end of bronchus of the same pa-
tient. (original magnification x100)
c: Histological feature of small-
sized adenocarcinoma with bron-
chioloalveolar carcinoma compo-
nent. (case 5 in table 2) (original
magnification x4) d: Histological
feature of small-sized adenocarci-
noma without bronchioloalveolar
carcinoma component. (case 24 in
table 2) (original magnification x4)
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RESULTS
We initiated our research with a pair of cell lines,
PL16T established from atypical adenomatous hyperplasia
and PL16B established from normal bronchial epithelium of
the same patient (Fig. 1a & 1b). The MCA-SSH genome-
scanning approach first involves isolation of CpG-rich Sma
I-digested fragments and generation of a methylation-specific
library by the MCA method reported previously by Toyota et
al.13 Then, using PL16T as the tester and PL16B as the driver,
we performed SSH to exclude sequences common to the
tester and driver populations. Finally, by T/A cloning and
differential screening, 229 clones from a total of 2134 clones
were selected for sequence analysis.
Among the 229 clones, 190 DNA fragments could be
sequenced with the ABI PRISM 310 Genetic Analyzer and
their adjacent sequences were obtained by a BLAST search.
From the 190 DNA fragments, 29 genes could be identified
(Table 1). In these 29 DNA fragments, 15 had a genomic
region that met the criteria for a CpG island (minimum
length, 200bp; GC content, 50%; CpG/GpC, 0.5). We
then used quantitative RT-PCR to analyze the relative ex-
pression levels between PL16T and PL16B. Among the 15
genes, apoptotic chromatin condensation inducer 1 (ACIN1)
showed significant difference of its expression level between
PL16T and PL16B and we finally selected the gene for
further analysis.
The genome structure of the ACIN1 gene is shown in
Fig. 2. The size of the captured DNA fragment was 670 base
pairs, including exon 17, intron 17, exon 18, and intron 18.
The methylation status of the locus at the 5= end of the cloned
DNA fragment of ACIN1 was examined by the bisulfite
sequencing technique in the 37 paired surgical specimens of
TABLE 1. List of the 29 genes identified in the DNA fragments isolated by MCA-SSH
Gene Full name
Location of the DNA
fragment CpGI*
Chromosomal
position
ABR active BCR-related gene intron2 yes 17p13.3
ACIN1 apoptotic chromatin condensation inducer 1 exon17 - intron17 - exon18 –
intron18
yes 14q11.2
ARHGAP10 rho-GTPase activating protein 10 intron9 no 4q31.23
Bmp8A bone morphogenetic protein 8 a intron6 no 1p34
CMIP C-maf-inducing protein intron1 yes 16q23
C20orf9 frame chromosome 20 open reading frame 9 intron6 no 6p21.3
DKFZP434H132 DKFZP434H132 protein exon1 yes 15q23
DUX4 double homeobox 4 exon1 yes 4q35.2
IGFL2 insulin growth factor-like family member 4 intron1 no 19q13.22
KCNJ14 potassium inwardly rectifying channel, subfamily J,
member 14
intron1 yes 19q13
KIAA KIAA0676 protein intron4 no 5q35.3
MSH5 mutS homolog 5 (E. coli) intron7 yes 6p21.3
MVD mevalonate (diphospho) decarboxylase intron8 no 16q24.3
NPTX1 neuronal pentraxin 1 exon5 - 3’ untranslated
region
yes 17q25.1-25.2
PKD1 polycystic kidney disease 1 (autosomal dominant) exon12 - intron12 yes 16q13.13
PLEKHG2 pleckstrin homology domain containing, family G
member 2
intron13 no 6q25.1
POLM polymerase (DNA directed), mu intron7 no 7p13
PRKAR1B protein kinase cAMP-dependent, regulatory type 1 intron6 no 7pter-p22
RASA3 RAS p21 protein activator 3 intron9 no 13q34
SALL4 sal-like 4 (Drosophila) intron1 no 20q13.13-q13.2
SH3BP2 SH3-domain binding protein 2 exon3 - intron3 - exon4 yes 4p16.3
SLC16A1 solute carrier family 16 (monocarboxylic acid
transporters) member 1
intron2 yes 1p12
SLC39A11 solute carrier family 39 (metal ion transporters)
member 11
intron6 yes 17q24-.q25.1
SPG7 spastic paraplegia 7, paraplegin 3’ untranslated region yes 16q24.3
STX8 syntaxin 8 intron6 no 17p.12
TANC TPR domain, ankyrin-repeat and coiled-coil-containing intron no 2q24.2
TRIM56 tripartite motif-containing 56 exon1 yes 7q22.1
USP18 ubiquitin specific protease18 intron3 yes 22q11.21
WNT7B wingless-type MMTV integration site family member
7B
intron2 no 22q13
* The relaxed criteria described previously were used for finding CpG islands: minimum length 200 bp; G  C  50%; observed CpG/expected CpG  60%.
Journal of Thoracic Oncology • Volume 1, Number 2, February 2006 ACIN1 Methylation in Lung Adenocarcinoma
Copyright © 2006 by the International Association for the Study of Lung Cancer 163
early lung adenocarcinoma and the adjacent normal tissues.
These specimens included 21 cases of adenocarcinoma with
BAC and 16 cases of adenocarcinoma without BAC (Fig. 1c
& 1d). The pathologic stage and clinical characteristics of the
cases are shown in Table 2 and 3. After bisulfite modification,
three to five clones from each specimen were sequenced and
examined for methylation status. We judged the specimen
methylated if all clones were methylated. As shown in Table
2 and Table 3, 30 of 37 (81%) tumor specimens were
methylated but only 9 of 37 (24%) adjacent noncancerous
tissues were methylated (P 0.05). All the cases in which the
adjacent noncancerous tissue was judged as methylated also
showed methylation in the tumor tissue (Table 2). There was
no correlation between pathologic stage and/or clinical char-
acteristics of the adenocarcinoma and methylation status
(Table 2). Interestingly, the frequency of methylated status in
the surrounding noncancerous tissue of the small-sized lung
adenocarcinomas without BAC was significantly (P  0.05)
higher than that of adenocarcinomas with BAC (Table 3).
However, there was no difference in tumor methylation status
between small-sized adenocarcinomas with BAC and those
without BAC (Table 3). Among the adenocarcinoma cases
with BAC component, the BAC/total tumor ratio did not
TABLE 2A. Summary of ACIN1 gene methylation and Clinicopathologic Features in Patients with Small-Sized
Adenocarcinoma with bronchioloalveolar carcinoma component of the lung
ACIN1
d
Classification of
small-sized
adenocarcinoma
Case
number
Pathologic
stagea Gender
Age
(years) SI
Diameter
(mm)
BAC/totalb
tumor area (%) WHO classificationc M(T) M(N)
1 IA F 56 520 13 100 pure BAC 2/4 2/4
2 IA F 57 0 12 100 pure BAC 5/5 4/4
3 IA F 80 900 20 60 mix BACacinar 4/5 4/5
4 IA F 77 0 9 100 pure BAC 4/4 1/4
5 IA F 49 0 20 100 pure BAC 5/5 4/5
6 IA F 58 0 10 100 pure BAC 5/5 3/4
7 IIA F 68 0 10 50 mix BACacinar 5/5 3/5
Adenocarcinoma 8 IA M 68 1620 20 30 mix BACacinar 5/5 3/5
with BAC 9 IIIA F 47 0 17 70 mix BACacinar 4/5 2/5
10 IA M 52 0 15 80 mix BACacinar 4/4 3/4
11 IA F 58 0 15 60 mix BACacinarpapi 4/4 2/4
12 IA F 56 4 20 50 mix BACacinar 4/4 3/4
13 IA F 47 0 15 80 mix BACacinarpapi 3/3 1/4
14 IA M 73 1100 20 40 mix BACacinar 4/4 3/4
15 IB M 56 0 15 60 mix BACacinar 4/5 4/5
16 IA M 78 550 14 80 mix BACacinar 5/5 2/5
17 IIIA M 55 700 20 30 mix BAC(mucinous)acinar 5/5 3/5
18 IA M 65 1000 11 90 mix BAC acinarsolid 5/5 3/5
19 IB M 72 1120 14 30 mix BAC papiacinar 5/5 3/5
20 IA M 81 0 16 30 mix BAC acinarsolid 5/5 5/5
21 IB M 57 900 20 30 mix BAC acinarsolid 5/5 2/4
aPathologic stage: I (IA and IB), II (IIA and IIB), III (IIIA and IIIB); SI: smoking index: (the number of cigarettes smoked/day) x years.
bBAC: bronchioloalveolar carcinoma, components of BAC in the cases were non-mucus except case number 18.
cmix: mixed adenocarcinoma; acinar: acinar adenocarcinoma; papi: papillary adenocarcinoma.
dM: methylate cytosine, five clones of the isolated DNA fragment were sequenced by bisulfite sequencing in 37 cases of lung adenocarcinoma (T) and the surrounding normal
tissue(N). The frequency of methylation in 5 end CpG sites of isolated DNA fragments of the ACIN1 gene were showed as the number of clones methylated /the number of clones
examined.
FIGURE 2. Genome structure of the ACIN1 gene and the
locations of CpG islands (full black boxes). The position of
the DNA fragment isolated by MCA-SSH is indicated by the
open box. C denotes the cytosine residues at the 5= end
of the isolated DNA fragment, with unknown methylation
status. During sodium bisulfite DNA modification, un-
methylated cytosine residues are converted to thymine,
whereas methylated cytosine residues are retained as cy-
tosine at the CpG site. After bisulfite DNA modification,
the DNA fragments were amplified by PCR using appro-
priate primers and their sequences were determined with
an automated sequencer.
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influenced the tumor methylation status or the noncancerous
tissue methylation status (Table 2).
We performed quantitative RT-PCR to measure expres-
sion levels of the ACIN1 gene in lung adenocarcinoma and
the adjacent normal tissue, using three specimens of lung
adenocarcinoma with BAC component and three specimens
of lung adenocarcinoma without BAC component (Fig. 3).
All the tumor tissues examined were methylated cases about
ACIN1 (Table 1), but there were no significant correlations
between the ACIN1 gene expression levels of lung adeno-
carciomas and their methylation status.
DISCUSSION
PL16T and PL16B are immortalized cell lines derived
from a precancerous lesion of lung adenocarcinoma and from
normal bronchial epithelium of the same patient.19 Therefore,
they represent a useful tool for investigation of early epige-
netic changes in lung adenocarcinoma. In this study, we
examined methylation status in these cell lines by a combi-
nation of MCA and SSH methods. We established that the
ACIN1 gene shows significant differences in methylation
status and expression level between PL16T and PL16B. The
ACIN1 (apoptotic chromatin condensation inducer 1) gene
encodes the protein Acinus, which is essential for apoptotic
chromatin condensation in vitro and is also important in the
induction of apoptotic chromatin condensation in cells.24 No
information about the hyper- or hypo-methylation of ACIN1
in cancer was previously available. We examined methyl-
ation status at the same locus in paired tissue specimens from
37 cases of small lung adenocarcinoma and the adjacent
TABLE 2B. Summary of ACIN1 gene methylation and Clinicopathologic Features in Patients with Small-Sized
Adenocarcinoma without bronchioloalveolar carcinoma component of the lung
ACIN1Classification of
small-sized
adenocarcinoma
Case
number
Pathologic
stage Gender
Age
(years) SI
Diameter
(mm)
BAC/total
tumor area WHO classification M(T) M(N)
● 22 IA F 76 0 20 0 mix papiacinar 4/4 4/4
23 IIA F 77 0 17 0 mix acinarsolid 5/5 3/4
Adenocarcinoma 24 IA M 62 0 13 0 mix acinarsolid 5/5 3/5
without BAC 25 IA M 66 440 18 0 mix acinarsolid 5/5 5/5
26 IA M 61 1480 15 0 mix solidacinarpapi 5/5 5/5
27 IIIB M 46 0 20 0 mix solidacinar 5/5 4/5
28 IA M 60 1600 18 0 mix solidacinarpapi 5/5 5/5
29 IIIA M 71 2700 18 0 mix solidacinar 4/5 4/5
30 IA M 63 860 15 0 papi 5/5 3/5
31 IA M 82 840 18 0 solid 4/4 4/5
32 IIIA M 46 0 13 0 papi 5/5 3/5
33 IA F 74 0 16 0 acinar 4/5 2/5
34 IA F 59 0 17 0 papi 4/5 3/5
35 IA M 62 1080 18 0 solid 5/5 5/5
36 IA M 59 430 15 0 acinar 5/5 5/5
● 37 IA M 69 980 15 0 solid 5/5 5/5
aPathologic stage: I (IA and IB), II (IIA and IIB), III (IIIA and IIIB); SI: smoking index: (the number of cigarettes smoked/day) x years.
bBAC: bronchioloalveolar carcinoma, components of BAC in the cases were non-mucus except case number 18.
cmix: mixed adenocarcinoma; acinar: acinar adenocarcinoma; papi: papillary adenocarcinoma.
dM: methylate cytosine, five clones of the isolated DNA fragment were sequenced by bisulfite sequencing in 37 cases of lung adenocarcinoma (T) and the surrounding normal
tissue(N). The frequency of methylation in 5 end CpG sites of isolated DNA fragments of the ACIN1 gene were showed as the number of clones methylated /the number of clones
examined.
TABLE 3. Frequency of methylation in lung adenocarcinoma and its surrounding noncancerous tissue
Cancerous legion Non-cancerous regionb
Methylation T with BACa T without BACa Total T with BAC T without BAC Total
 17 (81%) 13 (81%) 30 (81%) 2 (10%) 7 (44%) 9 (24%)
 4 (19%) 3 (19%) 7 (97%) 19 (90%) 9 (56%) 28 (76%)
Total 21 16 37 21 16 37
: Methylated cytosine residues were found in the 5 end CpG sites of the isolated DNA fragment in all of the clones examined; : Unmethylated cytosine residues were found
in at least one of the clones examined.
aT with BAC: tumor with BAC component; T without BAC: tumor without BAC component.
bThe difference between T with BAC and T without BAC in the frequency of methylation in the surrounding noncancerous region of lung adenocarcinoma was statistically
significant:, P 0.05
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normal tissue using bisulfite sequencing technique. The fre-
quency of methylation of ACIN1 in tumors was higher than
in the surrounding noncancerous tissue, both in tumors with
BAC component (21 patients, average age 61 years) and in
tumors without BAC component (16 patients, average age
64.6 years) (Tables 2 and 3). But there were no significant
differences of the frequencies of hypermethylation of ACIN1
between tumors with BAC and tumors without BAC. No
effect of gender, age or smoking index on methylation status
was also found. Our observation suggests that hypermethyl-
ation of this locus is a common event in the early stages of
lung adenocarcinoma, regardless of the histological subtype
of lung adenocarcinoma, such as adenocarcinoma derived
from AAH or BAC and de novo adenocarcinoma without
BAC component.
Clones from the surrounding normal tissue showed
various extents of methylation (Table 3), and we observed
that the methylation frequency of ACIN1 in normal tissue
was higher in cases of adenocarcinoma without BAC com-
ponent than in cases of adenocarcinoma with BAC compo-
nent (Tables 2 and 3). Two possible explanations may ac-
count for this observation. First, there may be diversity of
cellular methylation status in normal lung tissue, and the
methylation status of ACIN1 in normal tissue may determine
the histological type of the adenocarcinoma. Secondly, the
background methylation status of the normal lung tissue may
reflect degree of exposure to carcinogens such as cigarette
smoke or diesel exhaust.
The expression analysis of ACIN1 gene in this study
showed no correlation between the expression level of
ACIN1 and its methylation status (Fig. 3). Usually, the
methylation of CpG islands in promoter region was reported
to influence the expression level of the gene such as
p16INK4A.25 However, the methylated locus of ACIN1 gene
was located on the CpG islands in the exon-intron region.
Current evidence suggests that methylation of coding se-
quences or introns does not directly silence the expression
level of ACIN1 gene. Therefore, the differences of ACIN1
gene expression between PL16T and PL16B could not be
interpreted by the methylation at the locus detected in this
study. The potential methylation site of ACIN1 that may
influence expression is speculated to be located on the CpG
island in the promoter region of the gene. We believe that the
results of this study indicated that we detected one of the
hyper-methylated sites in the course of pulmonary adenocar-
cinogenesis and we may use the results to screen the high-risk
population for non-BAC type adenocarcinoma.
In this study, we found hypermethylation of the ACIN1
gene in not only early stage lung adenocarcinoma, but also
some non-tumorous regions of adenocarcinoma cases. These
results suggested that the methylation of ACIN1 gene is one
of the early events in the lung adenocarcinoma development
and also suggested the possibility to identify persons with
high risk of some type of lung adenocarcinoma. Nevertheless,
the role of methylation status in the development and malignant
progression of lung adenocarcinoma requires clarification.
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